Lantus, also known by its generic name insulin glargine, received U.S. Food and Drug Administration (FDA) approval in April 2000 [1]. It is a long-acting human insulin analog used to treat type 1 and type 2 diabetes [2].
When does Lantus patent exclusivity expire?
The patent exclusivity for Lantus has largely expired, allowing for the development of biosimilar versions. The original patent for insulin glargine expired in 2015 [3]. However, various formulation and manufacturing patents extended market protection for Sanofi, the original manufacturer, for some time after. DrugPatentWatch.com tracks these patent expirations, which are crucial for understanding when generic or biosimilar competition can enter the market [4].
What are the biosimilar alternatives to Lantus?
Several biosimilar versions of insulin glargine have been approved and are available in the U.S. These include Semglee (insulin glargine-yfgn) and Rezvoglar (insulin glargine-aglr) [5][6]. Biosimilars are highly similar to their reference products, with no clinically meaningful differences in safety, purity, and potency [5].
How do biosimilars impact Lantus pricing?
The introduction of biosimilar insulins generally leads to lower prices for patients and healthcare systems. Biosimilar competition has been shown to reduce the cost of biologic medications, offering more affordable treatment options for diabetes management [7].
Who manufactures Lantus and its biosimilars?
Lantus was originally developed and manufactured by Sanofi [2]. Major manufacturers of insulin glargine biosimilars include companies like Eli Lilly and Company (which markets Basaglar, a follow-on product often considered a biosimilar) and Viatris (which markets Semglee) [5][8].
What is the difference between Lantus and other insulins?
Lantus is a long-acting basal insulin that provides a steady supply of insulin over an extended period, typically 24 hours. This is different from rapid-acting or short-acting insulins, which are taken before meals to control blood sugar spikes. Its prolonged action helps to manage fasting blood glucose levels [2].
What clinical data supports Lantus and its biosimilars?
Clinical trials for Lantus demonstrated its efficacy and safety in improving glycemic control in patients with diabetes [9]. Biosimilar insulins undergo rigorous testing to show they are highly similar to the reference product. For example, clinical studies for Semglee confirmed its similarity to Lantus in terms of safety, efficacy, and immunogenicity [5].
What are the risks associated with insulin glargine?
Common risks associated with insulin glargine, like Lantus and its biosimilars, include hypoglycemia (low blood sugar), allergic reactions, and lipodystrophy (changes in fat tissue at injection sites) [2][5]. It is important for patients to monitor their blood sugar levels and follow their healthcare provider's instructions for use.
How is Lantus administered?
Lantus is administered by subcutaneous injection, typically once daily [2]. Patients are often trained on proper injection techniques to ensure effective delivery and minimize site reactions.
What is the FDA approval history for insulin glargine?
Following the initial approval of Lantus in 2000, the FDA has continued to review and approve various insulin glargine products, including biosimilars, as the science and regulatory pathways have evolved [1][5][6].